Skip to Content
Stock Analyst Update

UnitedHealth Reports Strong Q3, Conservative on 2021

Despite a conservative 2021 outlook, we're maintaining our fair value estimate for the narrow-moat company.

Mentioned:

Narrow-moat UnitedHealth Group (UNH) reported third-quarter operating results that beat Capital IQ consensus on the top and bottom lines, which allowed the organization to raise its adjusted earnings per share outlook for the year mildly. However, management also highlighted that its outlook for 2021 may be more conservative than usual given the ongoing headwinds related to the coronavirus pandemic and uncertain economic environment. So while our earnings estimate for 2020 appears slightly below below the firm's outlook range, our below-consensus view on 2021 may remain appropriate. Therefore, we are maintaining our fair value estimate of $304 per share, for now.

In the quarter, UnitedHealth turned in revenue of $65.1 billion, above consensus of $64.0 billion. Management highlighted strength in its Optum operations, particularly in its healthcare services business that bounced back from weak utilization figures in the second quarter. Year-over-year growth in volume and revenue per consumer were particularly strong. Also in insurance, continued expansion in its Medicare Advantage and Medicaid managed-care contracts helped offset weakening conditions in the employer market. However, management anticipates that the full effects of the economic weakening in terms of reduced insurance rolls and mix shifts to Medicaid are still to come.

On the bottom line, the firm beat analyst expectations and was able to increase its 2020 outlook slightly, despite expectations for ongoing pandemic conditions that resulted in increased outflows in the quarter. During the quarter, UnitedHealth generated $3.51 of adjusted earnings per share, lower than the year-ago period but higher than consensus ($3.08). Management highlighted that these results included voluntary COVID-19-related cost-sharing initiatives that pressured the medical cost ratio. Despite those ongoing outflows, management raised its earnings guidance for 2020 to $16.50-$16.75 from $16.25-$16.55.

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

Julie Utterback does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.